Summary

U.S. Anti-Biofilm Wound Dressing Market Summary

The U.S. anti-biofilm wound dressing market size was valued at USD 314.2 million in 2024 and is projected to reach USD 546.3 million by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The market's growth can be attributed to the growing prevalence of chronic and acute wounds owing to the increase in chronic diseases, including diabetes, cancer, cardiovascular diseases, and other autoimmune diseases.

According to the U.S. Centers for Disease Control and Prevention, as of 2021, over 38 million people, over 11% of the overall U.S. population, had diabetes. The country's increasing number of road accidents significantly contributes to the market's growth. According to the U.S. Department of Transportation’s National Highway Traffic Safety Administration, over 39,000 people died in road accidents in 2024. The growing number of road accidents increases the demand for wound care products with anti-biofilm properties, as these accidents can lead to severe burns and traumatic injuries. The increasing government and private investments in advanced wound care technologies to improve patient outcomes and lower healthcare costs further contribute to the market's growth.

Regulatory frameworks ensure safety and efficacy and promote the adoption of advanced antimicrobial dressings, while end-use concentration highlights the significance of key healthcare segments such as hospitals, specialty clinics, and outpatient clinics in driving demand.

Innovation remains crucial as companies invest heavily in R&D to develop dressings with enhanced anti-biofilm capabilities. In April 2025, Convatec announced its plans for the initial market launch of ConvaNiox, a new technology powered by a potent antimicrobial and antibiofilm agent, nitric oxide, which is supported by strong clinical evidence. ConvaNiox will be initially used for the management of diabetic foot ulcers (DFUs), which has been demonstrated to reduce the wound area three times faster and increase DFU healing by 60% in comparison to the standard of care.

The rising incidence of diabetes, alongside an aging demographic, further increases the demand, urging manufacturers to increase production and broaden their product ranges to cater to the sector's specific requirements. For instance, numerous companies have enhanced their manufacturing capabilities within the U. S. and fortified their distribution networks to serve healthcare providers better.

U.S. Anti-biofilm Wound Dressing Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. anti-biofilm wound dressing market report based on mode of mechanism, application, and end-use:

• Mode of Mechanism (Revenue, USD Million, 2018 - 2030)
• Physical
o Manual Debridement
o Pulse Electrical Field
o Ultrasound Debridement
• Chemical
o Ionic Silver
o Iodine
o EDTA
o Others
• Biological
o Dispersin B
o Lactoferrin
o Bacteriophage
o Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Chronic Wounds
o Diabetic Foot Ulcers
o Pressure Ulcers
o Venous Leg Ulcers
o Others
• Acute Wounds
o Surgical & Traumatic Wounds
o Burn Wounds
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Anti-biofilm Wound Dressing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related Market Outlook
3.2. Industry Value Chain Analysis
3.3. Regulatory Framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.4.3. Industry Challenges
3.4.4. Industry Opportunities
3.5. Industry Analysis Tools
3.5.1. Porter’s Five Forces Analysis
Chapter 4. U.S. Anti-biofilm Wound Dressing Market: Mode of Mechanism Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Anti-biofilm Wound Dressing Market: Mode of Mechanism Movement Analysis & Market Share, 2024 & 2030
4.3. Physical
4.3.1. Physical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Manual Debridement
4.3.2.1. Manual Debridement Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Pulse Electrical Field
4.3.3.1. Pulse Electrical Field Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.4. Ultrasound Debridement
4.3.4.1. Ultrasound Debridement Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Chemical
4.4.1. Chemical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Ionic Silver
4.4.2.1. Ionic Silver Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Iodine
4.4.3.1. Iodine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. EDTA
4.4.4.1. EDTA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Others
4.4.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Biological
4.5.1. Biological Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Dispersin B
4.5.2.1. Disperin B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Lactoferrin
4.5.3.1. Lactoferrin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. Bacteriophage
4.5.4.1. Bacteriophage Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. Others
4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Anti-biofilm Wound Dressing Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Anti-biofilm Wound Dressing Market: Application Movement Analysis & Market Share, 2024 & 2030
5.3. Chronic Wounds
5.3.1. Chronic Wounds Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. Diabetic Foot Ulcers
5.3.2.1. Diabetic Foot Ulcers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Pressure Ulcers
5.3.3.1. Pressure Ulcers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.4. Venous Leg Ulcers
5.3.4.1. Venous Leg Ulcers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.5. Others
5.3.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Acute Wounds
5.4.1. Acute Wounds Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. Surgical & Traumatic Wounds
5.4.2.1. Surgical & Traumatic Wounds Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. Burn Wounds
5.4.3.1. Burn Wounds Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Anti-biofilm Wound Dressing Market: End-Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Anti-biofilm Wound Dressing Market: End-Use Movement Analysis & Market Share, 2024 & 2030
6.3. Hospitals
6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Specialty Clinics
6.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Home Healthcare
6.5.1. Specialty Healthcare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. U.S. Anti-biofilm Wound Dressing Market - Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map
7.4. Position Analysis, 2024
7.5. Strategy Mapping
7.5.1. Expansion
7.5.2. Mergers & Acquisition
7.5.3. Partnerships & Collaborations
7.5.4. New Product Launches
7.5.5. Research and Development
7.6. Company Profiles
7.6.1. ConvaTec Inc.
7.6.1.1. Participant’s overview
7.6.1.2. Financial performance
7.6.1.3. Product benchmarking
7.6.1.4. Recent developments
7.6.2. Smith & Nephew PLC
7.6.2.1. Participant’s overview
7.6.2.2. Financial performance
7.6.2.3. Product benchmarking
7.6.2.4. Recent developments
7.6.3. Imbed Biosciences
7.6.3.1. Participant’s overview
7.6.3.2. Financial performance
7.6.3.3. Product benchmarking
7.6.3.4. Recent developments
7.6.4. Next Science
7.6.4.1. Participant’s overview
7.6.4.2. Financial performance
7.6.4.3. Product benchmarking
7.6.4.4. Recent developments
7.6.5. B. Braun Melsungen AG
7.6.5.1. Participant’s overview
7.6.5.2. Financial performance
7.6.5.3. Product benchmarking
7.6.5.4. Recent developments
7.6.6. 3M
7.6.6.1. Participant’s overview
7.6.6.2. Financial performance
7.6.6.3. Product benchmarking
7.6.6.4. Recent developments
7.6.7. Molnlycke Health Care AB
7.6.7.1. Participant’s overview
7.6.7.2. Financial performance
7.6.7.3. Product benchmarking
7.6.7.4. Recent developments
7.6.8. Coloplast
7.6.8.1. Participant’s overview
7.6.8.2. Financial performance
7.6.8.3. Product benchmarking
7.6.8.4. Recent developments
7.6.9. Lohmann & Rauscher
7.6.9.1. Participant’s overview
7.6.9.2. Financial performance
7.6.9.3. Product benchmarking
7.6.9.4. Recent developments